HK1023125A1 - Crystalline form of 4-Ä5-methyl-3-phenylisoxazol-4-ylÜbenzenesulfonamide - Google Patents

Crystalline form of 4-Ä5-methyl-3-phenylisoxazol-4-ylÜbenzenesulfonamide

Info

Publication number
HK1023125A1
HK1023125A1 HK00102376A HK00102376A HK1023125A1 HK 1023125 A1 HK1023125 A1 HK 1023125A1 HK 00102376 A HK00102376 A HK 00102376A HK 00102376 A HK00102376 A HK 00102376A HK 1023125 A1 HK1023125 A1 HK 1023125A1
Authority
HK
Hong Kong
Prior art keywords
ylübenzenesulfonamide
phenylisoxazol
methyl
crystalline form
crystalline
Prior art date
Application number
HK00102376A
Other languages
English (en)
Inventor
John J Talley
John R Medich
Kathleen T Mclaughlin
Henry T Guad
Edward E Yonan
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of HK1023125A1 publication Critical patent/HK1023125A1/xx

Links

Classifications

    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L23/00—Details of semiconductor or other solid state devices
    • H01L23/34—Arrangements for cooling, heating, ventilating or temperature compensation ; Temperature sensing arrangements
    • H01L23/40—Mountings or securing means for detachable cooling or heating arrangements ; fixed by friction, plugs or springs
    • H01L23/4006—Mountings or securing means for detachable cooling or heating arrangements ; fixed by friction, plugs or springs with bolts or screws
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L23/00—Details of semiconductor or other solid state devices
    • H01L23/34—Arrangements for cooling, heating, ventilating or temperature compensation ; Temperature sensing arrangements
    • H01L23/42—Fillings or auxiliary members in containers or encapsulations selected or arranged to facilitate heating or cooling
    • H01L23/427—Cooling by change of state, e.g. use of heat pipes
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L2924/00—Indexing scheme for arrangements or methods for connecting or disconnecting semiconductor or solid-state bodies as covered by H01L24/00
    • H01L2924/0001—Technical content checked by a classifier
    • H01L2924/0002—Not covered by any one of groups H01L24/00, H01L24/00 and H01L2224/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Power Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Computer Hardware Design (AREA)
  • General Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Liquid Crystal Substances (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
HK00102376A 1996-08-14 2000-04-19 Crystalline form of 4-Ä5-methyl-3-phenylisoxazol-4-ylÜbenzenesulfonamide HK1023125A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2437896P 1996-08-14 1996-08-14
PCT/US1997/015126 WO1998006708A1 (en) 1996-08-14 1997-08-12 Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide

Publications (1)

Publication Number Publication Date
HK1023125A1 true HK1023125A1 (en) 2000-09-01

Family

ID=21820280

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00102376A HK1023125A1 (en) 1996-08-14 2000-04-19 Crystalline form of 4-Ä5-methyl-3-phenylisoxazol-4-ylÜbenzenesulfonamide

Country Status (39)

Country Link
US (2) US6441014B2 (xx)
EP (2) EP0920422B1 (xx)
JP (2) JP3631763B2 (xx)
KR (1) KR100383148B1 (xx)
CN (1) CN1205193C (xx)
AP (1) AP1055A (xx)
AR (1) AR009244A1 (xx)
AT (1) ATE228117T1 (xx)
AU (1) AU722072B2 (xx)
BG (1) BG64259B1 (xx)
BR (1) BR9711151A (xx)
CA (1) CA2264104A1 (xx)
CZ (1) CZ297679B6 (xx)
DE (1) DE69717281T2 (xx)
DK (1) DK0920422T3 (xx)
EA (2) EA003754B1 (xx)
EE (1) EE04237B1 (xx)
ES (1) ES2188971T3 (xx)
GE (1) GEP20022636B (xx)
HK (1) HK1023125A1 (xx)
HU (1) HUP0400923A3 (xx)
IL (2) IL161224A0 (xx)
IS (1) IS1989B (xx)
LT (1) LT4551B (xx)
LV (1) LV12274B (xx)
NO (1) NO312461B1 (xx)
NZ (1) NZ334132A (xx)
OA (1) OA11298A (xx)
PL (1) PL191313B1 (xx)
PT (1) PT920422E (xx)
RO (1) RO120771B1 (xx)
RS (1) RS49671B (xx)
SI (1) SI9720059B (xx)
SK (1) SK283558B6 (xx)
TR (1) TR199900298T2 (xx)
TW (1) TW527350B (xx)
UA (1) UA52684C2 (xx)
WO (1) WO1998006708A1 (xx)
ZA (1) ZA977314B (xx)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199900298T2 (xx) * 1996-08-14 1999-05-21 G.D. Searle &Co. 4-(5-Metil-3-fenilizoksazol-4-il) BenzenS�lfonamidin kristal halinde bi�imi.
NZ333399A (en) 1997-12-24 2000-05-26 Sankyo Co Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
GB9810920D0 (en) * 1998-05-21 1998-07-22 Merck Sharp & Dohme Therapeutic use
EP1102755B1 (en) * 1998-08-07 2006-01-04 Chiron Corporation Substituted isoxazole derivatives as estrogen receptor modulators
AU1398899A (en) * 1998-11-12 2000-06-05 Algos Pharmaceutical Corporation Cox-2 inhibitors in combination with centrally acting analgesics
CN1349423A (zh) * 1999-03-01 2002-05-15 奥索-麦克尼尔药品公司 包含曲马多物质和选择性cox－2抑制剂药物的组合物
ATE284223T1 (de) * 1999-08-20 2004-12-15 Ortho Mcneil Pharm Inc Zusammensetzung enthaltend ein tramadol und ein antikonvulsives arzneimittel
US6403640B1 (en) * 1999-08-27 2002-06-11 Merck & Co., Inc. Method for treating chronic prostatitis or chronic pelvic pain syndrome
DE10032132A1 (de) * 2000-07-01 2002-01-17 Lohmann Therapie Syst Lts Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung
DK1419151T3 (da) 2001-08-15 2014-03-31 Pharmacia & Upjohn Co Llc Krystaller indeholdende et malatsyresalt af N-[2-(diethylamino)ethyl]-5-[(5-fluor-1,2-dihydro-2-oxo-3H-indol-3-yliden)methyl]-2,4-dimethyl-1H-pyrrol-3-carboxyamid, fremgangsmåder til fremstilling deraf og sammensætninger deraf
US20070072921A1 (en) * 2002-07-26 2007-03-29 Talley John J Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide
AU2003238668A1 (en) 2003-04-04 2004-10-25 Hetero Drugs Limited Novel crystalline forms of valdecoxib
PL1534305T3 (pl) 2003-05-07 2007-03-30 Osteologix As Leczenie zaburzeń chrząstek i kości solami strontu rozpuszczalnymi w wodzie
US20050182113A1 (en) * 2003-12-30 2005-08-18 Venkataraman Sundaram Method for preparing diaryl-substituted isoxazole compounds
US20050272787A1 (en) * 2004-05-19 2005-12-08 Eswaraiah Sajja Process for preparing crystalline form A of valdecoxib
WO2005120499A1 (en) * 2004-06-10 2005-12-22 Chandiran Thakashinamoorthy Form a of valdecoxib suitable for pharmaceutical formulations
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
ES2291780T3 (es) * 2004-06-28 2008-03-01 Grunenthal Gmbh Formas cristalinas del clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)fenol.
KR100591786B1 (ko) 2004-10-19 2006-06-26 휴먼팜 주식회사 프란루카스트를 함유하는 약학적 조성물 및 이의 제조 방법
EP1881959A1 (en) 2005-05-20 2008-01-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
JP2009537635A (ja) 2006-05-19 2009-10-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癲癇の処置のための共同−療法
US8809385B2 (en) 2008-06-23 2014-08-19 Janssen Pharmaceutica Nv Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CN103172583A (zh) * 2013-03-07 2013-06-26 深圳市资福药业有限公司 一种制备帕瑞昔布的方法
US10028904B2 (en) 2014-12-04 2018-07-24 Wisconsin Alumni Research Foundation Transdermal cannabinoid formulations
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
CN114441666B (zh) * 2020-11-05 2024-02-27 成都百裕制药股份有限公司 一种4-(5-甲基-3-苯基-4-异恶唑)苯磺酰氯中杂质的检测方法
IL305573A (en) 2021-03-15 2023-10-01 Saul Yedgar Hyaluronic acid conjugated with dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment or suppression of inflammatory diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
WO1996025405A1 (en) * 1995-02-13 1996-08-22 G.D. Searle & Co. Substituted isoxazoles for the treatment of inflammation
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US5643933A (en) * 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
TR199900298T2 (xx) * 1996-08-14 1999-05-21 G.D. Searle &Co. 4-(5-Metil-3-fenilizoksazol-4-il) BenzenS�lfonamidin kristal halinde bi�imi.
AU2003238668A1 (en) * 2003-04-04 2004-10-25 Hetero Drugs Limited Novel crystalline forms of valdecoxib
US20050272787A1 (en) * 2004-05-19 2005-12-08 Eswaraiah Sajja Process for preparing crystalline form A of valdecoxib

Also Published As

Publication number Publication date
SK13699A3 (en) 1999-07-12
EE9900053A (et) 1999-08-16
EP0920422A1 (en) 1999-06-09
EP0920422B1 (en) 2002-11-20
HUP0400923A3 (en) 2007-11-28
RO120771B1 (ro) 2006-07-28
ZA977314B (en) 1998-08-14
AP1055A (en) 2002-04-04
US6441014B2 (en) 2002-08-27
EA200000891A1 (ru) 2001-02-26
YU7499A (sh) 2000-03-21
ES2188971T3 (es) 2003-07-01
EE04237B1 (et) 2004-02-16
NZ334132A (en) 2000-06-23
CN1233243A (zh) 1999-10-27
HUP0400923A2 (hu) 2004-08-30
NO990541D0 (no) 1999-02-05
DE69717281T2 (de) 2003-09-04
EA199900200A1 (ru) 1999-06-24
IL161224A0 (en) 2004-09-27
US20010003752A1 (en) 2001-06-14
EA001472B1 (ru) 2001-04-23
LV12274A (lv) 1999-05-20
AU4093697A (en) 1998-03-06
IL128255A (en) 2004-06-20
UA52684C2 (uk) 2003-01-15
LT99024A (en) 1999-07-26
GEP20022636B (en) 2002-02-25
BG64259B1 (bg) 2004-07-30
LV12274B (en) 1999-09-20
DE69717281D1 (de) 2003-01-02
ATE228117T1 (de) 2002-12-15
US7135489B2 (en) 2006-11-14
PT920422E (pt) 2003-03-31
CZ33499A3 (cs) 1999-06-16
AP9901458A0 (en) 1999-03-31
TR199900298T2 (xx) 1999-05-21
DK0920422T3 (da) 2003-03-17
NO312461B1 (no) 2002-05-13
BG103155A (en) 1999-11-30
PL191313B1 (pl) 2006-04-28
JP2000506542A (ja) 2000-05-30
CZ297679B6 (cs) 2007-03-07
WO1998006708A1 (en) 1998-02-19
JP3631763B2 (ja) 2005-03-23
TW527350B (en) 2003-04-11
IS4961A (is) 1999-01-29
BR9711151A (pt) 1999-08-17
JP2005015497A (ja) 2005-01-20
NO990541L (no) 1999-02-05
SI9720059A (sl) 1999-12-31
US20030004200A1 (en) 2003-01-02
EP1283203A1 (en) 2003-02-12
AR009244A1 (es) 2000-04-12
AU722072B2 (en) 2000-07-20
KR100383148B1 (ko) 2003-05-09
IL128255A0 (en) 1999-11-30
EA003754B1 (ru) 2003-08-28
LT4551B (lt) 1999-10-25
PL331607A1 (en) 1999-08-02
SI9720059B (sl) 2011-11-30
CN1205193C (zh) 2005-06-08
KR20000029994A (ko) 2000-05-25
OA11298A (en) 2003-10-22
IS1989B (is) 2005-02-15
CA2264104A1 (en) 1998-02-19
RS49671B (sr) 2007-11-15
SK283558B6 (sk) 2003-09-11

Similar Documents

Publication Publication Date Title
HK1023125A1 (en) Crystalline form of 4-Ä5-methyl-3-phenylisoxazol-4-ylÜbenzenesulfonamide
PL329875A1 (en) Derivatives of carbolin
PL329195A1 (en) Derivatives of 6-phenylpyridol-2-amine
PL327998A1 (en) Novel derivatives of 19-nor-pregnene
PL311736A1 (en) Derivatives of 1h-imidazoles
PL346544A1 (en) Crystalline forms of eto2
NZ331886A (en) Crystalline metallophosphates
HU9702480D0 (en) New polymorphe modification of doxazosin-mesylate
NZ331885A (en) Crystalline metallophosphates
CY2590B2 (en) Preparation of 1-butyl-4-piperidinylmethylamine
GB9602704D0 (en) Structure of perculator
EP0719831A3 (en) Crystalline polyester
PL337612A1 (en) Crystalline form of roxyfiban
HU9702479D0 (en) New polymorphe modification of doxazosin-mesylate
GB2328397B (en) Manufacture of elongate members
ZA95694B (en) Novel derivatives of tetramethylcyclopropane
GB2335923B (en) Amino-butyrate derivatives of venoms
PL325602A1 (en) Alternative crystalline form of thazophenelone
PL313849A1 (en) Beta-aminoesters of o-hydrobenzylamides
EP0923519A4 (en) PRODUCTION OF HALOALKYNOLS
PL327915A1 (en) Crystalline progestagenes
TW358610U (en) Improvement of inter-com
TW304520U (en) Improved structure of groyne
SI1107980T1 (en) CRYSTALLINE FORMS OF EtO2C-CH2-(R)Cgl-Aze-Pab-OH
CA79365S (en) Set of dinnerware

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090812